Analyst Price Targets — ORGO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 20, 2025 12:10 pm | — | BTIG | $9.00 | $5.14 | TheFly | Organogenesis price target raised to $9 from $7 at BTIG |
| March 5, 2025 12:21 pm | — | Morgan Stanley | $6.00 | $6.01 | TheFly | Organogenesis price target raised to $6 from $4 at Morgan Stanley |
| June 28, 2024 8:01 am | Brooks O'Neil | Lake Street | $5.00 | $2.64 | TheFly | Organogenesis initiated with a Buy at Lake Street |
Latest News for ORGO
Wound closure at 12 weeks was a key highlight, indicating the product's efficacy.
Organogenesis Holdings Inc. is a cash-generative wound care leader trading at distressed multiples due to overestimated short-term reimbursement risks. PuraPly AM achieved statistically significant results in a randomized controlled trial for diabetic foot ulcers, strengthening ORGO's clinical and commercial position. ORGO faces a 25–38% revenue decline in 2026 from CMS reimbursement changes, but RCT-backed evidence…
The trial demonstrated statistically significant wound closure at 12 weeks when comparing PuraPly AM plus standard of care to standard care alone.
CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the completion of a randomized controlled trial (RCT) evaluating PuraPly®AM plus standard of care (SOC) versus SOC…
Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025 CANTON, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the successful…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ORGO.
U.S. House Trading
No House trades found for ORGO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.